Meissa Vaccines develops vaccines to prevent viral respiratory infections, with a lead investigational live attenuated RSV vaccine candidate. The company’s platform leverages synthetic biology and genetic engineering, including proprietary reverse genetics and human codon deoptimization, to design live attenuated vaccine candidates. Its technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta, and Meissa is a resident company at Johnson & Johnson Innovation – JLABS in South San Francisco. The proceeds from the recent financing will be used to expand the team and conduct Phase 1 and Phase 2 clinical trials for the RSV vaccine. Meissa also plans to support a broader viral vaccine pipeline based on its synthetic biology technology. The company’s leadership includes cofounder and CEO Martin Moore, Ph.D., and cofounder Roderick Tang. Meissa Vaccines develops live attenuated respiratory vaccines using proprietary reverse genetics and human codon deoptimization technologies licensed from Emory University. The company is advancing an investigational RSV vaccine and is developing candidates for human metapneumovirus and parainfluenza using the same platform. Meissa completed a successful FDA pre-IND meeting and has finished manufacturing clinical trial material for Phase 1 and Phase 2 testing in adults and children. Prior funding included several SBIR grants from the NIH to support R&D. The company is a resident at Johnson & Johnson Innovation JLABS in South San Francisco and is led by cofounder and CEO Martin Moore, Ph.D., alongside cofounder Roderick Tang. Recent hires to the board include industry veterans Kenneth Kelley and William Daly to support clinical advancement. Meissa Vaccines is developing vaccines to prevent viral respiratory infections, with programs targeting respiratory syncytial virus (RSV) and rhinovirus. Its lead asset is a live attenuated RSV vaccine candidate intended for infants. The company plans to use the seed proceeds to support an investigational new drug (IND) filing for that lead candidate. The technology was sourced from Dr. Martin Moore’s laboratory at Emory University. Meissa was co-founded by Dr. Martin Moore and Dr. Roderick Tang and is led by Dr. Moore as CEO. The team includes personnel experienced in conducting vaccine clinical trials, and the company is a resident of Johnson & Johnson Innovation, JLABS in South San Francisco.

Total raised

$33M

Funding rounds

3

Latest round

Series A

Latest activity

Sep 2019